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sumer PriceHospital Services index.RESULTS: Total chargeswere $9.8; $9.6; and $9.5
billion for 2006, 2007, and2008, respectively. Thehighest total chargeswere associated
with events for which Medicaid was the expected primary payer ($3.3 billion), fol-
lowed by Medicare ($2.2 billion) for each year In 2006, charges were $2.0 billion for
self-paid events, and $1.7 billion for privately insured events; this relationship was
reversed in 2007 and 2008. Adjusted mean per-event charges were $19,413; $19,560;
and $17,690 for 2006, 2007, and 2008, respectively. Compared to events covered by
private insurance, adjusted charges for Medicare- andMedicaid-covered events were
statistically significantlyhigher,while self-paid eventshad significantly lower charges
(p 0.001 for all years). Age, number of comorbidities, presence of cardiac or respira-
tory disease, gastrointestinal hemorrhage, and acute pancreatitis were significantly
positively associated with total charges (p  0.001 for all). CONCLUSIONS: The eco-
nomic burden of opioid abuse on the healthcare system is substantial and associated
charges are related to insurance status. Factors associated with charges for events
related to opioid abuse ormisuse were also identified, resulting in better understand-
ing of costs of opioid abuse andmisuse.
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ANTIDEPRESSANT TREATMENT PATTERNS, HEALTH CARE UTILIZATION AND
COST AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
Isenberg K1, Eisenberg D2, Sanchez R3, Alvir J3, Wang J4, Gu T2, White J4
1Blue Cross Blue Shield of Missouri, Kansas City, MO, USA, 2HealthCore, Inc., Wilmington, DE,
USA, 3Pfizer, Inc., New York, NY, USA, 4WellPoint, Inc., Thousand Oaks, CA, USA Background:
This study evaluated treatment patterns, health care resource utilization, and cost associated
with the use of escitalopram, duloxetine, venlafaxine and desvenlafaxine for MDD.
OBJECTIVES: To assess total and disease-related healthcare costs among patients
diagnosedwithMDD.METHODS: This retrospective cohort study used administra-
tive claims from a large health plan. Patients aged 18-64 with 1medical claim for
MDD and  1 pharmacy claim for branded formulations of escitalopram, dulox-
etine, venlafaxine or desvenlafaxine were identified between January 1, 2009 and
November 30, 2009. Patients were excluded if they had a claim for bipolar disorder
or were not continuously enrolled during the study period. Proportion of days
covered (PDC), healthcare utilization and cost were assessed using descriptive sta-
tistics. Generalized linear model (GLM) with the log link function and a gamma
distribution were also used to examine the association between healthcare cost
while controlling for demographic and clinical characteristics. RESULTS: A total of
45,913 patients were identified. Almost half initiated on escitalopram (47%), with
the remaining patients on duloxetine, 25%, venlafaxine, 21%, and desvenlafaxine,
7%. MDD-specific health care cost was lowest for desvenlafaxine ($1948) followed
by escitalopram ($2065), duloxetine ($2867), and venlafaxine ($3078). Likewise, total
cost of care was lowest for desvenlafaxine ($11,480), followed by escitalopram
($11,879), venlafaxine ($13,380) and duloxetine ($16,384). Analyses that controlled
for variables including age, gender, region, pre-index total all cause-related health
care costs, PDC and used desvenlafaxine as reference group, indicated a significant
difference in MDD-related cost (duloxetine: cost ratio (CR)1.270, venlafaxine:
CR1.388, p0.0001 for both; escitalopram: CR0.986, p0.3994) and total cost (du-
loxetine: CR1.139, venlafaxine: CR1.051, p0.05 for both; escitalopram:
CR0.946, p0.0017). CONCLUSIONS: In this population, there appears to be an
association between use of desvenlafaxine and lower post-index MDD specific and
total cost of care, compared to duloxetine and venlafaxine. There may be unob-
servable factors that were not accounted for influencing these results.
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UTILIZATION OF PALIPERIDONE LONG-ACTING INJECTION AMONG MEDICARE
ADVANTAGE AND MEDICARE PRESCRIPTION DRUG PLAN MEMBERS
Suehs B1, Li Y1, Howe A2, Doshi D2, Pasquale M1, Uribe C3, Patel N1
1Competitive Health Analytics, LLC, Louisville, KY, USA, 2Janssen Scientific Affairs, LLC,
Titusville, NJ, USA, 3Competitive Health Analytics, Humana, Louisville, KY, USA
OBJECTIVES: To describe the demographics, prescription drug utilization, medica-
tion adherence, and pharmacy costs for Medicare Advantage and Medicare Pre-
scription Drug Plan members initiated on paliperidone palmitate (PALI-PALM), a
long-acting antipsychotic for treating schizophrenia. METHODS: The Humana
pharmacy claims database was used to identify Medicare Advantage andMedicare
Prescription Drug Plan members with a pharmacy claim for PALI-PALM between
September 1, 2009, and December 31, 2010. Six-month preindex and postindex
observation periods were used to assess medication utilization and medication-
related costs for patients starting PALI-PALM.Medication possession ratio (MPR) for
PALI-PALMwas calculated using a fixed denominator of sixmonths.RESULTS: Four
hundred forty-one patients met the inclusion criteria. Mean (SD) age was 46.9
(12.6) years. Three hundred ninety-seven patients (90.0%) had a low-income sub-
sidy (LIS), and 331 (75.1%) were dually eligible for Medicaid. Patients initiated on
PALI-PALM received amean of 1.9 (1.0) unique antipsychotics during the preindex
period. One hundred six patients (24%) who had initiated on PALI-PALM had re-
ceived 3 or more antipsychotics during the preindex period. Antidepressant
(56.9%), anticonvulsant (49.2%), and antiparkinsonism (39.0%) drugs were themost
frequently observed nonantipsychotic mental health medications during the pre-
index period. Compared with the preindex period, use of benzodiazepines and
nonbenzodiazepine anxiolytics decreased during the postindex period (benzodiaz-
epines: 10.0% versus 7.3%; McNemar’s test, p0.034; nonbenzodiazepine anxiolyt-
ics: 12.5% versus 8.4%; McNemar’s test, p0.007). Two hundred forty-one patients
(54.6%) displayed an MPR for PALI-PALM 0.80 during the 6-month postindex pe-
riod. Analysis regarding medication-related costs will be presented in the poster.
CONCLUSIONS: Amajority of Medicare members who had initiated on PALI-PALM
had a LIS and dual eligibility. Use of multiple antipsychotics during the preindex
period was common among members initiated on PALI-PALM. We observed a re-
duction in the use of benzodiazepines and nonbenzodiazepine anxiolytics among
members receiving PALI-PALM.
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TREATMENT PATTERNS, RESOURCE UTILIZATION AND COSTS ASSOCIATED
WITH GUANFACINE IMMEDIATE RELEASE VERSUS GUANFACINE EXTENDED
RELEASE AMONG CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/
HYPERACTIVITY DISORDER (ADHD)
DiBello J1, Sikirica V1, Samuelson T2, Xie J3, He T2, Erder MH1
1Shire Development, LLC, Wayne, PA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Analysis
Group, Inc., New York, NY, USA
OBJECTIVES: Guanfacine is a centrally-acting alpha-2 adrenoceptor agonist avail-
able in immediate (GIR) and extended release (GXR) formulations. GIR is FDA-
approved for hypertension, but is prescribed off-label for ADHD. GXR is US ap-
proved for symptomatic treatment of pediatric ADHD as mono- or adjunctive
therapy. No outcomes study has compared the two formulations. This study de-
scriptively compares treatment patterns, resource utilization, and cost, between
children and adolescents with ADHD initiating treatment with GIR versus GXR.
METHODS: Patients, aged 6-17, with  1 claim for GIR or GXR from November 1,
2009-December 30, 2010 were identified from a large US commercial medical and
pharmacy claims database. Patients had  1 primary diagnosis of ADHD (ICD-9
codes: 314.00, 314.01) during the baseline period, no prior guanfacine use or hyper-
tension diagnosis, and continuous eligibility for 6-months pre- and post-guanfa-
cine initiation. Patient characteristics, resource utilization and costs were descrip-
tively compared using Chi-square and student t-tests. Treatment patterns were
compared using Log-rank test. RESULTS: The GIR and GXR cohorts included 743
and 2,344 patients, respectively. At baseline, patients initiating GIR had signifi-
cantly more adjunctive therapy use (59.1% versus 54.6%, p0.03), higher total
health care costs ($4250 vs. $3384), and utilization ( 1 hospitalization [8.6% vs.
4.6%],  1 emergency room visit [17.2% vs. 14.0%]) than GXR initiators (all p0.05).
After 6-months, GIR patients switched or discontinuedADHD treatmentmore than
GXR (21.3% vs. 12.8%; 73.5% vs. 53.7%, respectively (all p0.01)). Health care utili-
zation remained significantly greater for GIR patients ( 1 hospitalization [5.4% vs.
3.8%]; p0.05;  1 emergency room visit [16.0% vs. 12.5%]; p0.02), while total
health care costs ($4214 vs. $3934, p0.41) were equivalent. CONCLUSIONS: Pre-
liminary findings indicate children and adolescents may have higher rates of dis-
continuation/switching, and resource utilization when treated with GIR than GXR;
costs were not different. Further adjusted analyses are underway comparing out-
comes between the two drugs.
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UTILITY IMPROVEMENTS FROM A DEPRESSION HOME SUPPORT PROGRAM FOR
OLDER AFRICAN AMERICANS: RESULTS FROM THE BEAT THE BLUES TRIAL
Pizzi LT1, Jutkowitz E1, Law M2, Komura S2, Gitlin L3
1Thomas Jefferson University, Philadelphia, PA, USA, 2Jefferson School of Pharmacy,
Philadelphia, PA, USA, 3Johns Hopkins University, Baltimore, MD, USA
OBJECTIVES: While utility improvements from depression treatments have been
studied, little research has examined utility improvements from non-pharmaco-
logical treatments in older minorities. The objective of this study was to measure
utility improvements from Beat the Blues (BTB), a non-pharmacological program
for older depressed African Americans inwhich licensed senior center social work-
ers meet with participants at home for up to 10 sessions over 4 months to assess
care needs, make referrals/linkages, provide depression education, instruct in
stress reduction techniques, and use behavioral activation to identify goals and
steps to achieve them. METHODS: Utility (EQ-5D) was measured in a single-blind
parallel group randomized clinical trial comparing BTB to wait list control. Patients
were enrolled between 2009 and 2010, were African American, age  55, had pos-
itive screen for depression (PHQ-95), English speaking, and cognitively intact.
EQ-5D was administered at T1 (baseline), T2 (4 months) and T3 (8 months). Partic-
ipants receiving control at T1 were switched to BTB at T2 and followed to T3;
participants receiving BTB at T1were switched to observation at T2 and followed to
T3 (“post-BTB”). RESULTS: EQ-5D sample sizes for the study groups were T1-T2:
BTB69; control66, and T2-T3: BTB79; post-BTB70. EQ-5D index values for BTB
versus control at T1 were 0.5701 (0.20 SD) versus 0.5705 (0.21 SD) and improved to
0.6638 (0.22 SD) versus 0.6308 (0.20 SD) at T2 (T1-T2 within group improvements
were 0.0937 and 0.0603 for BTB versus control). EQ-5D index in the post-BTB group
held from T2-T3 (slight 0.0093 within group increase). Participants switched to BTB
from control from T2-T3 showed improvement (0.0655 within group increase).
CONCLUSIONS: BTB resulted in meaningful and sustained utility improvement, in
the range of depression treatments previously studied. Findings inform discus-
sions about health gains which can be expected from non-pharmacological treat-
ments in depressed older, underserved African Americans.
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UTILITY SCORES ASSOCIATED WITH THE WORLD HEALTH ORGANISATION
DRINKING RISK-LEVEL CLASSIFICATION IN ALCOHOL DEPENDENCE
Sanglier T1, Laramée P1, Millier A2, Guennec M3, Marteau F1, Daeppen JB4
1Lundbeck S.A.S., Issy-les-Moulineaux cedex, France, 2Creativ-Ceutical, Paris, France, 3Université
Victor Segalen Bordeaux 2, Bordeaux, France, 4Lausanne University Hospital, Lausanne,
Switzerland
BACKGROUND: Extensive research exists estimating the effect hazardous alcohol
use on morbidity and mortality, but little research quantifies the association be-
tween alcohol consumption andutility scores in patientswith alcohol dependence.
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In the context of comparative research, the World Health Organisation (WHO)
proposed to categorise the risk for alcohol-related acute and chronic harm accord-
ing to patients’ average daily alcohol consumption. OBJECTIVES: To estimate util-
ity scores associated with each category of the WHO drinking risk-level classifica-
tion in patients with alcohol dependence (AD). METHODS: We used data from
CONTROL, an observational cohort study including 143 AD patients from the Alco-
hol Treatment Center at Lausanne University Hospital, followed for 12 months.
Average daily alcohol consumption was assessed monthly using the Timeline Fol-
low-back method and patients were categorised according to the WHO drinking
risk-level classification: abstinent, low, medium, high and very high. Other mea-
sures as sociodemographic characteristics and utility scores derived from the Eu-
roQoL 5-Dimensions questionnaire (EQ-5D) were collected every three months.
Mixed models for repeated measures were used to estimate mean utility scores
associated with WHO drinking risk-level categories. RESULTS: A total of 143 pa-
tients were included and the 12-month follow-up permitting the assessment of
1318 person-months. At baseline the mean age of the patients was 44.6 (SD 11.8)
and the majority of patients was male (63.6%). Using repeated measures analysis,
utility scores decreased with increasing drinking levels, ranging from 0.80 in absti-
nent patients to 0.62 in patients with very high risk drinking level (p0.0001).
CONCLUSIONS: In this sample of patients with alcohol dependence undergoing
specialized care, utility scores estimated from the EQ-5D appeared to substantially
and consistently vary according to patients’ WHO drinking level.
PMH46
EXAMINING THE DIFFERENCES BETWEEN PATIENTS TREATED FOR MAJOR
DEPRESSIVE DISORDER COMPARED TO THOSE WHO DO NOT REALIZE THEY
HAVE MAJOR DEPRESSIVE DISORDER
Gross HJ1, Vietri J2, Chapnick J1
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA
OBJECTIVES:Major Depressive Disorder (MDD) has a profound negative impact on
sufferers’ lives. This analysis sought to identify differences in patient characteris-
tics and outcomes associatedwith self-report of depression and use of prescription
treatment within a positively-screened MDD population. METHODS: Data were
taken from the US 2011 National Health and Wellness Survey (n75,000), a cross-
sectional Internet-based survey representative of US adults. Patients with MDD
were identified using the Patient Health Questionnaire (PHQ-9). Health-related
quality of life (HRQoL) was assessed with the SF-12 Health Survey (SF-12v2), and
activity impairment was measured with the Work Productivity and Activity Im-
pairment questionnaire (WPAI). Comparisons between patient groups were made
with chi-square tests for categorical variables and ANOVA for continuous
variables. RESULTS: PHQ-9 scores identifiedMDD in 6.3% of respondents (n4,720);
33.5% (n1,583) reported depression and prescription treatment, 30.0% (n1418)
reported depression without prescription treatment, and 36.4% (n1719) did not
self-report depression. Compared to those who did not self-report depression,
treated patients were more likely to have severe depression according to PHQ-9
scores (32.5% vs. 22.2%), had lower mental HRQoL (28.5 vs. 37.3), and more activity
impairment (60.5% vs. 47.4%) (ps0.001); however, fewer treated patients visited
the emergency room in the past 6 months (25.0% vs. 21.3%, p0.001). Patients who
did not report depression were more likely to have completed college (34.6% vs.
30.6%) and had higher incomes (37.6% with incomes over $50,000 vs. 32.4%), but
were less likely to have insurance (70.5% vs. 80.6%), and those with insurance were
less likely to have prescription drug coverage (60.2% vs. 74.4%) (ps0.001).
CONCLUSIONS: Patients who had MDD according to PHQ-9 but did not report de-
pression had less severe depression and a highermental QoL than treated patients,
but still had poor health outcomes. Less comprehensive insurance coverage may
be a barrier in seeking treatment.
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WHAT MAKES PEOPLE GENERALLY SATISFIED WITH MENTAL HEALTH
SERVICES?
Sohn M1, Barrett H2, Talbert J1
1University of Kentucky, Lexington, KY, USA, 2KY Dept. for Behavioral Health, Developmental &
Intellectual Disabilities, Frankfort, KY, USA
OBJECTIVES: The purpose of this study is to identify factors that predict whether
clientswill respond that theywere “generally satisfied”with services received from
Kentucky Community Mental Health Centers (CMHCs) in 2010. METHODS: Ken-
tucky Cabinet for Health and Family Services, Department for Behavioral Health
Developmental and Intellectual Disabilities (BHDID) conducted a survey to evalu-
ate consumers’ satisfaction with services delivered at the CMHCs in Kentucky. The
surveywas administered at outpatient clinics operated by CMHCs. The validity and
reliability of the survey were reviewed and a logistic regression model was devel-
oped using respondents’ characteristics and their responses about several aspects
of services. RESULTS: During the fiscal year 2010 (7/1/2009  6/30/2010), 117,526
adult patients visited Kentucky CMHCs and 7,029 of them participated in the sur-
vey, resulting in a 5.98% penetration rate. Logistic regression analyses show that
positive perceptions of access, quality and participation in treatment planning
significantly increase positive responses for general satisfaction by 21%, 27% and
5%, respectively. (dy/dx 0.21, 0.27 and 0.05, p0.05) Females are shown to bemore
likely to respond positively on general satisfaction (dy/dx 0.01, p0.05). Age, race
and regional characteristics (rural/urban) were not significantly related to re-
sponses to general satisfaction at the 95% confidence level. CONCLUSIONS: Re-
sponses to general satisfaction are more associated with responses to other do-
mains than respondents’ demographic characteristics. More specifically, the
domains of access, quality, and participation in treatment planning are stronger
predictors of a positive response on the “general satisfaction” question, suggesting
that more attention to those domains of service could positively influence mental
health care recipients’ responses regarding general satisfaction.
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VALIDATION OF PSPSQ MEASURING PATIENT SATISFACTION WITH
PSYCHIATRIC PHARMACY SERVICES
Sakharkar PR, Luu HA, Shankar GS, Law AV
College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA
OBJECTIVES: To assess psychometric properties of the Patient Satisfaction with
Pharmacist Services Questionnaire (PSPSQ) in a pharmacist-managed outpatient
psychiatric care clinic.METHODS: This descriptive, cross-sectional study was con-
ducted at a pharmacist-managed psychiatric care clinic in a behavioral healthcare
facility in Southern California between Nov. 2011 and Jan. 2012. Patients were
included if theywere18 years of age and able to read English. PSPSQ consists of 22
items assessed on a four point Likert scale, and hypothesized to have three do-
mains: patient-pharmacist relationship, quality of care and overall satisfaction.
This study was approved by the Institutional Review Board for exempt status.
PSPSQ has been previously tested for face and content validity and is being vali-
dated in other pharmacist managed Disease State Management clinics. Data col-
lected following patients’ visit were analyzed descriptively. Correlations were ex-
amined between age, gender, education, insurance status and patient satisfaction.
Scale reliability was assessed using Cronbach’s alpha and construct validity using
factor analysis. RESULTS: Thirty-five participants completed the survey. Mean age
of participants was 41 years, 54% were male, 37.9% were Caucasian and Hispanic
each, 81% had some college education, and 80% were covered by private health
insurance. Cronbach’s alpha of the tool was 0.971 indicating very high reliability.
After excluding two items, factor analysis yielded 19 items loading on three factors
accounting for 79.6% of the variance. Only one item loaded on a factor different
than hypothesized. The overall mean score of 3.5/4 indicated patient satisfaction
with the pharmacist services they received. Patients with private insurance
showed greater satisfaction compared to others (p0.05). CONCLUSIONS: Our re-
sults suggest that the PSPSQ can serve as a reliable and valid tool for measuring
patient satisfaction with pharmacist clinical services in a community/ambulatory
care setting. Further research is needed to confirm its utility in other pharmacy
practice settings.
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SEVERITY OF AUTISM SPECTRUM DISORDERS: EFFECT ON CAREGIVER BURDEN
AND SATISFACTION WITH SCHOOL DISTRICT SERVICES
Vohra R1, Madhavan S2, Khanna R3
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of
Pharmacy, Morgantown, WV, USA, 3University of Mississippi, University, MS, USA
OBJECTIVES: To assess the impact of severity of autism spectrum disorders (ASD)
on caregiver burden and satisfaction with school district services.METHODS: Sur-
vey datawas collected from 301 primary caregivers of childrenwith ASD. Caregiver
burden was measured using the Caregiver Strain Questionnaire (CGSQ) and ASD
severity in childrenwasmeasured using the ChildhoodAutismRating Scale-Parent
version (CARS-P) for functional impairments and Developmental Behavior Check-
list- Parent version (DBC-P24) for behavior problems. Children with ASD were clas-
sified into high and low severity subgroups based on the scores received on CARS-P
and DBC-P24, respectively. One-way analysis of variance (ANOVA) was performed
to assess differences in caregiver burden scores and satisfaction with seven types
of school district services between high and low severity subgroups. One-way AN-
COVA was performed to determine the mediating effect of caregiver burden be-
tween ASD severity and satisfaction with school district services. RESULTS: An
overall significant effect on caregiver burden scoreswas observed for both behavior
problems (F (1,299) 55.4, p0.001) and functional impairments (F (1,299)  42.5,
p0.001) sub-groups. Higher scores were reported for the high behavior problems
(Mean8.3, S.E0.13) and the high functional impairments groups (Mean 8.4,
S.E0.15). Satisfactionwith all school district services except for occupational ther-
apy differed significantly between the severity sub-groups. Caregivers of children
with ASD in high behavior problems and high functional impairments groups re-
ported lower satisfaction with services. The ANCOVA, however, showed no signif-
icant differences in service satisfaction between the severity sub-groups suggest-
ing a mediating role of caregiver burden. CONCLUSIONS: Severity of a child’s ASD
as defined by a combination of the extent of functional impairments and behavior
problems was found to be associated with higher caregiver burden and greater
dissatisfaction with services. Clinical diagnosis of ASD severity alone may not
predict the extent of unmet school service needs.
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PSYCHIATRISTS’ PREFERENCES FOR ATTRIBUTES OF ANTIPSYCHOTIC
MEDICATIONS TO TREAT SCHIZOPHRENIA: A CONJOINT ANALYSIS
Gelhorn H1, Gries KS2, Cho C3, Thompson C4, Fastenau J5
1United BioSource Corporation, Golden, CO, USA, 2United BioSource Corporation, Seattle, WA,
USA, 3Janssen Pharmaceuticals, Inc., Titusville, NJ, USA, 4United BioSource Corporation,
Bethesda, MD, USA, 5Janssen Scientific Affairs, LLC, Titusville, NJ, USA
OBJECTIVES: To examine psychiatrists’ preferences for specific attributes of anti-
psychotics in the treatment of schizophrenia.METHODS: A discrete choice exper-
iment (DCE) was administered to psychiatrists to examine 7 attributes of antipsy-
chotics (efficacy, mode of administration, formulary access, onset of action, dosing
frequency, safety, and side effects). Psychiatrists were presented with 18 total
choices and asked to indicate which of 2 hypothetical medications they preferred.
Choices were divided among 3 profiles of patients with schizophrenia (average
patient, symptomatic nonadherent patient, and chronic nonadherent patient). De-
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